背景:为业界ADC的临床开发提供参考,我们分析了抗体-药物偶联物(ADC)临床试验的前景和特点.
方法:在Cite系列PharmaIntelligence(Trialtrove数据库)中搜索了由赞助商发起的用于癌症药物治疗的ADC的临床试验,并从多角度分析了这些临床试验的景观和特点,比如数字,阶段,status,适应症,和临床试验的目标。
结果:截至2022年12月31日,总共启动了431项临床试验,以研究用于癌症药物治疗的ADC。过去10年的数量是前11年的5.5倍。这些临床试验涉及47种适应症,包括乳腺癌,淋巴瘤(淋巴瘤,非霍奇金和淋巴瘤,霍奇金),未指明的实体瘤,膀胱癌和肺癌(肺癌,非小细胞癌和肺癌,小细胞癌)。至于这五个适应症中的每一个,已经进行了50多项临床试验,占比高达48.50%(454/936)。ADC涉及38个目标,相对集中。其中,ERBB2(HER2)和TNFRSF8(CD30)涉及100多个注册临床试验,和TNFRSF17(BCMA),NECTIN4和CD19在10+试验中。这五个目标的临床试验占总数的79.02%(354/448)。这些临床试验中有多达93.97%(405/431)探索了生物标志物与疗效之间的相关性。临床试验中应用的批次(治疗线)高达45.91%(292/636)是第二线。截至2022年12月31日,54.52%(235/431)的临床试验已完成或终止。
结论:ADC是肿瘤学临床试验研究和开发的热点,但是迹象表明,目标,阶段,和已注册的批次目前似乎相对集中。本研究提供了全面的分析,可以帮助研究人员/开发人员快速掌握相关知识以评估产品,并为未来的研究提供新的线索和思路。
BACKGROUND: To provide reference for clinical development of ADCs in the industry, we analyzed the landscape and characteristics of clinical trials about antibody-drug conjugates (ADCs).
METHODS: Clinical trials to study ADCs used for the pharmacotherapy of cancers initiated by the sponsor were searched in the Cite line Pharma Intelligence (Trialtrove database), and the landscape and characteristics of these clinical trials were analyzed from multiple perspectives, such as the number, phases, status, indications, and targets of the clinical trials.
RESULTS: As of December 31, 2022, a total of 431 clinical trials have been initiated to study ADCs used for the pharmacotherapy of cancers, and the number of the last 10 years was 5.5 times as large as the first 11 years. These clinical trials involved 47 indications, including breast cancer, lymphoma (lymphoma, non-Hodgkin\'s and lymphoma, Hodgkin\'s), unspecified solid tumor, bladder cancer and lung cancer (lung, non-small cell cancer and lung, small cell cancer). As for each of these five indications, 50 + clinical trials have been carried out, accounting for as high as 48.50% (454/936). ADCs involve 38 targets, which are relatively concentrated. Among them, ERBB2 (HER2) and TNFRSF8 (CD30) involve in 100 + registered clinical trials, and TNFRSF17 (BCMA), NECTIN4 and CD19 in 10 + trials. The clinical trials for these five targets account for 79.02% (354/448) of the total number. Up to 93.97% (405/431) of these clinical trials explored the correlation between biomarkers and efficacy. Up to 45.91% (292/636) of Lots (lines of treatment) applied in the clinical trials were the second line. Until December 31, 2022, 54.52% (235/431) of the clinical trials have been completed or terminated.
CONCLUSIONS: ADCs are a hotspot of research and development in oncology clinical trials, but the indications, targets, phases, and Lot that have been registered are seemingly relatively concentrated at present. This study provides a comprehensive analysis which can assist researchers/developer quickly grasp relevant knowledge to assess a product and also providing new clues and ideas for future research.